
Weight-loss drugs like Semaglutide and Tirzepatide, originally for diabetes and obesity treatment, are increasingly used for rapid weight loss without medical supervision, as seen in Delhi clinics where patients report side effects. Concurrently, these drugs influence dietary habits globally, prompting supermarkets and restaurants to offer smaller, high-protein meals tailored to users' altered appetites, reflecting a shift in food consumption patterns linked to GLP-1 medications.
The articles present a largely neutral perspective focusing on medical and consumer behavior aspects without political framing. One highlights clinical concerns about unsupervised drug use in India, while the other discusses market adaptations in Western countries. Both sources emphasize health and lifestyle impacts rather than political implications, representing healthcare providers' caution and consumer market responses.
The overall tone is mixed, combining cautionary accounts of health risks from unsupervised drug use with observations of evolving consumer food trends. The first article conveys concern over misuse and side effects, while the second adopts an informative tone about changing dietary behaviors and market adaptations, balancing apprehension with neutral reporting on lifestyle shifts.
Each source's own headline, political lean, and sentiment — so you can see framing differences at a glance.
| Source | Their headline | Bias | Sentiment |
|---|---|---|---|
| thehindu | Karan Gokani: Ozempic is coming for your restaurant plate | Center | Positive |
| indianexpress | 'Doctor, I started this after seeing it on Instagram': Tales of weight-loss drugs in Delhi's OPDs | Center | Neutral |
indianexpress broke this story on 24 Apr, 07:47 am. Other outlets followed.
Well-covered story — coverage matches public importance.
Institutions and figures named across source coverage.
Select a news story to see related coverage from other media outlets.